Harvard Bioscience 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Harvard Bioscience reported Q3 2026 revenue of $22.2 million, up 8% year over year and toward the high end of its guidance range, marking its second consecutive quarter of strong revenue growth.
- Adjusted gross margin was 57.1%, at the low end of the outlook range, and adjusted EBITDA was $1.8 million, or 7.9% of revenue, compared with $2 million, or 9.6% of revenue, in Q3 2025.
- Growth was driven by CRO and distribution sales and strong demand for organoids, lytics, respiratory devices, inhalation products, and telemetry; the NPI portfolio contributed over 11% of total revenue.
- Americas revenue was $11.3 million, up 9% year over year; Europe revenue was $6.3 million, down 5% (3% lower on a constant currency basis); and APAC revenue was $4.6 million, up 29%. China revenue was $2.8 million, up 31%.
- GAAP diluted EPS was negative 58 cents and adjusted EPS was negative 6 cents. Cash used in operations through 9 months was $0.6 million, and the company ended the quarter with $4.9 million in cash and cash equivalents and net debt of $35.1 million.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and welcome to the third quarter 2026 Harvard Bioscience earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question, you will need to press star 11 on your touch-tone telephone. Please note, this call may be recorded. I would like to turn the call over to Taylor Krafchik, Senior Vice President at Ellipsis.
Please go ahead. Thank you, operator.
Good morning, everyone. Thank you for joining the Harvard Bioscience third quarter 2026 earnings conference call. Leading the call today will be John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer. In conjunction with today's recorded call, we have provided a presentation that will be referenced during our remarks that is posted to the investor relations section of our website at investor.harvardbioscience.com. Please note that statements made in today's discussion that are not historical facts, including statements on management's expectations of future events or future financial performance, are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current views of Harvard Bioscience's management, and Harvard Bioscience assumes no obligation to update or revise any forward-looking statements. Actual results may differ materially from those expressed or implied.
Please refer to today's press release, the Harvard Bioscience Form 10-Q, and other filings with the Securities and Exchange Commission for additional disclosures on forward-looking statements and the risks, uncertainties, and contingencies associated therewith. During the call, management will also reference certain non-GAAP financial measures, which can be useful in evaluating the company's operations related to our financial condition and results. These non-GAAP measures are intended to supplement GAAP financial information and should not be considered a substitute. Reconciliations of GAAP to non-GAAP measures are provided in today's earnings press release. I will now turn the call over to John.
John, please go ahead. Thank you, Taylor, and good morning, everyone.
In the third quarter, we delivered another solid quarter of top-line performance with 8% revenue growth, driven by strength across key preclinical platforms and double-digit momentum in products for organoids, fluidics, and our new product innovation. To give a high-level summary before Mark dives into the detailed financials, our results were in line with our expectations. Revenue came in at $22.2 million, representing 8% growth year-over-year, marking our second consecutive quarter of strong revenue growth. Adjusted gross margin was 57.1%, including higher volume in CMT products, increased sales through distribution partners, and growth in China, which carried lower gross margins. Adjusted EBITDA was $1.8 million, reflecting the same factors that impacted gross margin. Strong sales to CRO customers were driven by sales of our telemetry, respiratory, and inhalation products.
CRO sales are up meaningfully year to date, reflecting healthy demand as biopharma customers increasingly rely on external research partners. We also saw continued growth from our biopharma customers. Across the broader drug development landscape, industry tailwinds remain supportive to drive future growth. Preclinical drug candidate pipelines are expanding as pharma and biotech companies prepare for the upcoming 2030 patent cliff, with industry forecasts projecting a 7% increase in clinical trial starts over the coming years. This steady demand is reflected in our telemetry business, which is up mid-single digits year to date, demonstrating that in vivo safety and efficacy monitoring remains an indispensable step. Turning to our product portfolio, we saw robust customer demand for our preclinical technologies. Double-digit preclinical growth in the quarter was driven by exceptional performance in respiratory and inhalation.
Looking at our CMT portfolio, we were pleased to see strong double-digit revenue gains in our MEA products for organoids, both in Q3 and year to date. Our new product innovation portfolio continues to contribute meaningfully to our total revenue. Researchers are adopting our organoid technologies to generate highly predictive human-relevant data, directly aligning our innovation pipeline with the industry's transition toward New Approach Methodologies. In China, our distribution partners and localization strategy are delivering results, as revenue grew 31% in Q3. All three localized BTX electroporation product lines are now fully available and shipping in the Chinese market. Looking ahead, we continue to make progress in localizing new product lines to position us for continued regional momentum. Our revamped commercial team is delivering encouraging results.
Building on the sales realignment led by our new head of commercial, we established a dedicated key accounts group, which is focused on managing and expanding relationships with our largest customers, specifically our top-tier pharmaceutical, CRO, and biotech customers. Sales through Fisher Scientific North America have more than doubled year to date following the expansion of our distribution agreement last year, reinforcing the strength of our diversified channel strategy. Turning to our operational initiatives, we continue to make steady progress on Project Viking, our manufacturing consolidation plan, which remains on target for completion in the first quarter of 2027. During the third quarter, we successfully completed the relocation of our amino acid analyzer product line to our Cambridge, U.K. facility. We began shipping fluidics products out of our Minneapolis facility using a parallel build approach to ensure uninterrupted delivery to our customers.
As a reminder, we remain on track for Project Viking to generate $3 million in cost savings in 2027 and $4 million annually thereafter. These savings will contribute directly to adjusted EBITDA. Additionally, our newly formed scientific advisory board held its inaugural meeting in August. We will hold quarterly meetings going forward. The input from this group of industry leaders will help guide our technology roadmap. Since its creation, the members of the scientific advisory board have already provided me and our executive team with excellent industry insight and counsel. Turning to our outlook. Based on our year-to-date performance and our commercial momentum, we are reaffirming our full year 2026 revenue guidance of 3%-5% growth, as well as our adjusted gross margin target of 57%-59%. As noted in our earnings release, we've updated our full year adjusted EBITDA range.
This adjustment directly reflects the effect from higher sales volume of lower margin legacy products and of shipments in China and through our distribution partners. While the product mix carries a lower gross margin, our operating expense remains disciplined, and we are guiding to EBITDA growth in Q4 at the midpoint of our outlook. In summary, Harvard Bioscience delivered solid top-line performance in the third quarter. Our core platforms are performing well, our commercial initiatives are driving volume, and our operational milestones under Project Viking remain firmly on schedule. We are confident in the trajectory of the business and our positioning for 2027. With that, I will turn the call over to Mark for a detailed review of our financials.
Mark? Thank you, John. I will start my comments with our third quarter 2026 financial results, the details of which can be found starting on slide four of the earnings presentation posted to our IR site.
Slide four, revenue of $22.2 million was up 8% year-over-year and towards the high end of our guidance range in the second quarter in a row of strong revenue growth. The growth was primarily attributable to continued demand from CROs and robust sales from our distribution partners. By product, we had a strong quarter in organoids, fluidics, and respiratory devices. We are encouraged by the strong demand for organoid-related products, with our broader new product innovation, NPI portfolio, attributing over 11% of total revenue as we work to expand our NPI contribution. In addition, we continue to see growth in telemetry in our preclinical platform.
Adjusted gross margin of 57.1% was at the low end of our outlook range as we continue to see greater demand for some of our lower margin legacy products, had a higher contribution from our distribution channel, and saw continued strength in China, where we generate a lower margin. As we stated last quarter, driving sales of our higher margin NPI products is a priority, but we are not going to miss opportunities to sell any of our products as we drive scale, and we expect to realize significant benefits once our manufacturing consolidation is complete in early 2027. As a reminder, we have provided an adjusted gross margin reconciliation in the release to show the impact of restructuring, which is in the other line. A point for our investors is we operate our business assuming the impact of depreciation, amortization, and stock compensation costs.
In addition, as we expand our Made in China initiative, we expect to improve our margins in that market. OpEx increased $0.8 million in the quarter. As we have mentioned, we restored salaries, merit, and bonus potential this year, which is the primary reason for higher OpEx and reflects a normalized cost structure. This investment is offsetting our improvements from higher revenue, but we will see improved leverage in our returns in 2027. Operating loss was $1.2 million compared to income of $0.2 million in quarter three 2025. Adjusted operating income was $1.2 million, 5.3% operating margin, down from $1.5 million, 7.4% operating margin in Q3 last year. Adjusted operating income was lower primarily because of expenses being normalized. Adjusted EBITDA came in within our guidance range at $1.8 million, 7.9% EBITDA margin, down from $2 million, 9.6% EBITDA margin in quarter three 2025.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
